HTI医药2025年5月第三周周报：三生辉瑞巨大交易落地，持续推荐创新药-20250601

Investment Rating - The report maintains a positive outlook on innovative drugs and related sectors, recommending continuous attention to innovative pharmaceuticals and biotech companies [1][6][25]. Core Insights - The $6 billion deal between 3SBio and Pfizer is expected to further stimulate the innovative drug market, indicating strong demand for Chinese innovative drug assets despite geopolitical tensions [1][26]. - The A-share pharmaceutical sector outperformed the market, with a 1.8% increase during the third week of May 2025, while the overall index fell by 0.6% [1][9][27]. - The report highlights strong performance in specific sub-sectors such as chemical raw materials (+8.8%), chemical preparations (+5.1%), and biological products (+4.0%) [1][15][27]. Summary by Sections Continuous Focus on Innovative Drugs - The report emphasizes the high growth potential of innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Huadong Medicine, and 3SBio, among others [1][6][25]. A-Share Pharmaceutical Sector Performance - In the third week of May 2025, the A-share pharmaceutical sector ranked first among Shenwan primary industries, with notable individual stock performances [1][9][27]. Hong Kong and U.S. Pharmaceutical Sector Performance - The report notes that the Hong Kong and U.S. pharmaceutical sectors outperformed their respective markets during the same period, with significant gains in specific stocks [1][21][28].